Skip to main content

Blood Disease

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

QIAGEN
QIAGENGermany - Hilden
1 program
QIAstat-Dx® BCID GN and GPF Plus AMR PanelsN/A1 trial
Active Trials
NCT05305534Completed2,142Est. Aug 2025
Labcorp
LabcorpBURLINGTON, NC
1 program
Homologous Blood TransfusionPHASE_31 trial
Active Trials
NCT03548766Unknown12Est. Dec 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
LabcorpHomologous Blood Transfusion
QIAGENQIAstat-Dx® BCID GN and GPF Plus AMR Panels

Clinical Trials (2)

Total enrollment: 2,154 patients across 2 trials

NCT03548766LabcorpHomologous Blood Transfusion

Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping

Start: Sep 2018Est. completion: Dec 202112 patients
Phase 3Unknown
NCT05305534QIAGENQIAstat-Dx® BCID GN and GPF Plus AMR Panels

QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study

Start: Dec 2023Est. completion: Aug 20252,142 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.